Chadrick E Denlinger, MD, Michael D Keller, BS, Marty W Mayo, PhD, R

Slides:

Advertisements

Similar presentations

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Advertisements

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3 Cell Physiol Biochem 2016;40:

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Michael F. Nentwich, MD, Benjamin A. Bohn, MD, Faik G

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis-inducing.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL James.

Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage Steffen.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.

Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase.

Volume 42, Issue 2, Pages (February 2005)

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo

Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer David R. Jones, MD, Christopher.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Ground glass opacity of the lung: The veil that needs lifting

Circulating tumor DNA: Solid data from liquid biopsies

Enhancement of Apo2L/TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)–induced apoptosis in non–small cell lung cancer cell lines by chemotherapeutic.

MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 Ji-guang Zhang,

Miral R. Sadaria, MD, Amy E. Reppert, MD, Jessica A

Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small.

How should we treat air leaks?

BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non- small Cell Lung Carcinoma In Vitro Wenyan Li, MD, PhD, Bo Li, MD,

Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A2 inhibition Jessica.

SUMO Promotes HDAC-Mediated Transcriptional Repression

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Support Your Specialty

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner,

Military surgeons just want to have fun

A first start for lung transplantation?

Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell.

Commentary: Tag, you're it

Inhibition of nuclear factor κB by IκB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation Takaaki.

Chadrick E. Denlinger, MD, Brian K. Rundall, DO, Michael D

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Attachment disorder in thoracoabdominal surgery

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Volume 16, Issue 11, Pages (November 2008)

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Sequence-dependent enhancement of paclitaxel toxicity in non–small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin Dao M. Nguyen, MD, FRCSC,

Arsenic Induces Human Keratinocyte Apoptosis by the FAS/FAS Ligand Pathway, Which Correlates with Alterations in Nuclear Factor-κB and Activator Protein-1.

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Toll-like receptor 4 inhibition attenuates ischemia-reperfusion injury in rats: Will it work in human beings? Chadrick E. Denlinger, MD The Journal.

Aritoshi Hattori, MD, Kenji Suzuki, MD

Who should decide margin length in pulmonary excision of lung cancer?

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Combined proteasome and histone deacetylase inhibition in non–small cell lung cancer Chadrick E Denlinger, MD, Michael D Keller, BS, Marty W Mayo, PhD, R.Michael Broad, PhD, David R Jones, MD The Journal of Thoracic and Cardiovascular Surgery Volume 127, Issue 4, Pages 1078-1086 (April 2004) DOI: 10.1016/S0022-5223(03)01321-7

Figure 1 A, NSCLC cells were treated with butyrate (0-5000 μmol/L) for 24 hours. Cell viability was determined on the basis of crystal violet uptake. B, NSCLC cells were incubated in the presence or absence of butyrate (500 μmol/L), and nuclear HDAC activity was determined. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1078-1086DOI: (10.1016/S0022-5223(03)01321-7)

Figure 2 A and B, NSCLC cells were transfected with either the 3x-κB reporter gene or cotransfected with Gal4-p65 and the Gal4-luciferase reporter gene and treated with nothing, butyrate, bortezomib (bortz), or butyrate and bortezomib (*P = .04). C, A549 cells were similarly treated, and Northern blot analysis for IL8 was performed. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1078-1086DOI: (10.1016/S0022-5223(03)01321-7)

Figure 3 A, H358, H460, and A549 cells were treated with nothing, bortezomib (bortz), bortezomib and butyrate, or butyrate alone. Western blots were performed with antibodies for p21, p53, and β-tubulin. B, NSCLC cells were treated as noted above and analyzed by means of FACS analysis. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1078-1086DOI: (10.1016/S0022-5223(03)01321-7)

Figure 4 NSCLC cells were treated with nothing, butyrate, bortezomib (bortz), or combined butyrate and bortezomib. Cell survival was determined by means of crystal violet assay (*P = .01, †P = .06). The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1078-1086DOI: (10.1016/S0022-5223(03)01321-7)

Figure 5 A, NSCLC cells were treated with nothing, sodium butyrate, bortezomib (bortz), or butyrate and bortezomib. Apoptosis was assessed and quantified by means of DNA fragmentation (A, *P = .02), caspase-3 activation (B, *P = .03), and flow cytometry (C). The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1078-1086DOI: (10.1016/S0022-5223(03)01321-7)